Clinical Trial Results

Showing: All studies [change]
Condition: Cancer Location: Springfield, Missouri 25 trials found
New Search
Filter
Trial Phase
Study Type
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
PHASE2INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
N/AOBSERVATIONAL Anchorage, Alaska +4 more
RECRUITING
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
PHASE2INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
PHASE3INTERVENTIONAL Washington D.C., District of Columbia +4 more
RECRUITING
Galleri® in the Medicare Population.
NAINTERVENTIONAL Fort Smith, Arkansas +4 more
RECRUITING
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
PHASE2INTERVENTIONAL Kingman, Arizona +4 more
RECRUITING
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
PHASE2, PHASE3INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
N/AOBSERVATIONAL Fort Smith, Arkansas +4 more
RECRUITING
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
PHASE3INTERVENTIONAL Huntsville, Alabama +4 more
RECRUITING
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
N/AOBSERVATIONAL Birmingham, Alabama +4 more
RECRUITING
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
PHASE3INTERVENTIONAL Bakersfield, California +4 more
RECRUITING
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
PHASE2INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
PHASE3INTERVENTIONAL Gilbert, Arizona +4 more
RECRUITING
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
N/AOBSERVATIONAL Fairbanks, Alaska +4 more
RECRUITING
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
N/AOBSERVATIONAL Hartford, Connecticut +4 more
RECRUITING
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
PHASE3INTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
PHASE3INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Filter Trials
Trial Phase
Study Type